New Zealand signs deal to secure 1.5 mn doses of Pfizer, BioNTech COVID-19 vaccine

New Zealand government has reportedly signed a deal with Pfizer Inc and Germany’s BioNTech to secure 1.5 million doses of potential COVID-19 vaccine. Research, Science & Invation Minister Megan Woods said in a statement that government is in talks with or drug companies as well to ensure sufficient COVID-19 vaccines for whole population.

Pfizer-BioNTech vaccine, BNT162b2, is one of leing COVID-19 vaccine candidates in race to get regulatory approval in United States, Cana, and Europe. UK government h anunced on July 20 that it has signed a binding agreement with BioNTech/Pfizer to secure 30 million doses of vaccine. 

vaccine candidate is based on BioNTech’s proprietary mRNA techlogy and supported by Pfizer’s global vaccine development and manufacturing capabilities. vaccine candidate is being evaluated in a global Phase 3 study which is currently underway at more than 120 clinical sites worldwide. trial has enrolled around 37,000 participants with more than 28,000 volunteers have received ir second vaccination.

Re: Mexico Pays vance To Procure Safe COVID-19 Vaccines Under WHO's COVAX

Re: WHO Chief: COVID-19 Vaccine Will Be Allocated Based On ACT-Accelerator Principles

Vaccine race amid COVID spre

New Zealand has reported a successful containment of vel coronavirus and stopped community transmission through tough lockdown, backed by aggressive testing. However, procurement of potential vaccine is necessary to prevent ar wave of infection. global vaccine race intensified after Russia gave regulatory approval to a COVID-19 vaccine, Sputnik V, in August. 

Preliminary results from two early-phase n-randomised trials of Sputnik V showed major side effects over 42 days and induce antibody responses within 21 days, said study published in Lancet earlier in September. leing peer-reviewed medical journal said that doctors conducted trials for two-part vaccine which contains a recombinant evirus 26 (r26) vector and a recombinant evirus 5 (r5) vector.

“ human eviral vector platform, which is at heart of Russian vaccine, has been validated in more than 250 clinical studies over deces and has been found to be safe and free of potential negative long-term effects,” statement re.

Re: Indonesia Has 'strongest Vaccine Production Capacity In Souast Asia', Says China

Re: UK To Begin Trials To Test If Anti-TB BCG Vaccine Works Against COVID-19